Encyclopedia of AIDS

Living Edition
| Editors: Thomas J. Hope, Douglas Richman, Mario Stevenson

Epidemiology of AIDS-Defining Malignancies

Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-9610-6_20-1

Definition

AIDS-defining malignancies are a subset of HIV-associated malignancies that include Kaposi sarcoma, some forms of non-Hodgkin lymphoma, and invasive cervical cancer. KS along with PCP are among the first diseases that comprised the original definition of AIDS “in the United States.” Subsequently, non-Hodgkin lymphoma (1985) and invasive cervical cancer were added (CDC 1992). Compared to non-AIDS-defining malignancies, Kaposi sarcoma and non-Hodgkin lymphoma demonstrated the highest incidence in the early AIDS epidemic (see “ History of the AIDS Epidemic”). As shown in Fig. 1, with the introduction of highly active antiretroviral therapy (HAART) in 1996, the incidence patterns of these cancers with the exception of cervical cancer dropped significantly. It is hypothesized that HAART restores immune function and delays progression to AIDS. However, even with the improved clinical outcome, HAART has not eliminated the risk of AIDS-defining malignancies. HIV-positive persons...

Keywords

Cervical Cancer Immune Reconstitution Inflammatory Syndrome Invasive Cervical Cancer Primary Effusion Lymphoma Multicenter AIDS Cohort Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis. 2006;19:14–9.PubMedCrossRefGoogle Scholar
  2. Bratcher LF, Sahasrabuddhe VV. The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agent Cancer. 2010;5:8.PubMedCrossRefPubMedCentralGoogle Scholar
  3. Breen EC, Hussain SK, Magpantay L, Jacobson LP, Detels R, Rabkin CS, Kaslow RA, Variakojis D, Bream JH, Rinaldo CR, Ambinder RF, Martinez-Maza O. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1303–14.PubMedCrossRefPubMedCentralGoogle Scholar
  4. Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol. 2003;4:22–9.PubMedCrossRefGoogle Scholar
  5. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1–19.Google Scholar
  6. Clarke B, Chetty R. Postmodern cancer: the role of human immunodeficiency virus in uterine cervical cancer. Mol Pathol. 2002;55(1):19–24.PubMedCrossRefPubMedCentralGoogle Scholar
  7. Clarke MA, Wentzensen N, Mirabello L, Ghosh A, Wacholder S, Harari A, Lorincz AT, Schiffman M, Burk RD. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(12):2125–37.Google Scholar
  8. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ, for the HIV/AIDS Cancer Match Study. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006;20(12):1645–54.PubMedCrossRefGoogle Scholar
  9. Franceschi S, Dal Maso L, Rickenbach M, Polesel J, Hirschel B, Cavassini M, Bordoni A, Elzi L, Ess S, Jundt G, Mueller N, Clifford GM, and the Swiss HIV Cohort Study. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer. 2008;99:800–4.PubMedCrossRefPubMedCentralGoogle Scholar
  10. Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, Bouchardy C, Dehler S, Jundt G, Ess S, Bordoni A, Konzelmann I, Frick H, Dal Maso L, Elzi L, Furrer H, Calmy A, Cavassini M, Ledergerber B, Keiser O, and the Swiss HIV Cohort Study. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103:416–22.PubMedCrossRefPubMedCentralGoogle Scholar
  11. Hamilton-Dutoit SJ, Pallesen G, Franzmann MB, Karkov J, Black F, Skinhoj P, Pedersen C. AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol. 1991;138(1):149–63.PubMedPubMedCentralGoogle Scholar
  12. Husain S, Widney D, Jacobson L, Breen E, Levine A, Detels R, Zhang Z, Martínez-Maza O. Elevated serum levels of CXCL13 precede HIV-associated non-Hodgkin’s lymphoma. Infect Agent Cancer. 2010;5 Suppl 1:A24.CrossRefGoogle Scholar
  13. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92(22):1823–30.CrossRefGoogle Scholar
  14. Levine AM. AIDS-related malignancies: the emerging epidemic. J Natl Cancer Inst. 1993;85(17):1382–97.PubMedCrossRefGoogle Scholar
  15. Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies an international perspective. Hematol Oncol Clin North Am. 2003;17:673–96.PubMedCrossRefGoogle Scholar
  16. Nunnari G, Smith JA, Daniel R. HIV-1 Tat and AIDS-associated cancer: targeting the cellular anti-cancer barrier? J Exp Clin Care Res. 2008;27:3.CrossRefGoogle Scholar
  17. Pantanowitz L, Michelow P. Review of human immunodeficiency virus (HIV) and squamous lesions of the uterine cervix. Diagn Cytopathol. 2010;39(1):65–72.CrossRefGoogle Scholar
  18. Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, Bouchardy C, Furrer H, Hasse B, Levi F, Probst-Hensch NM, Schmid P, Franceschi S, and the Swiss HIV Cohort Study. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS. 2008;22:301–6.PubMedCrossRefGoogle Scholar
  19. Seaberg EC, Wiley D, Martinez-Maza O, Chmiel JS, Kingsley L, Tang Y, Margolick JB, Jacobson LP. Cancer incidence in the multicenter AIDS cohort study before and during the HAART era. Cancer. 2010;116:5507–16.PubMedCrossRefPubMedCentralGoogle Scholar
  20. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ, Engels EA. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753–62.PubMedCrossRefPubMedCentralGoogle Scholar
  21. Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, Hidalgo J, Lourtau L, Neaton JD, Tambussi G, Abrams DI. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007;21:1957–63.PubMedCrossRefGoogle Scholar
  22. Simard EP, et al. Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis. 2010;51(8):957–62.PubMedCrossRefPubMedCentralGoogle Scholar
  23. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2011;117:1089–96.PubMedCrossRefPubMedCentralGoogle Scholar
  24. Spagnuolo V, Galli L, Salpietro S, Gianotti N, Guffanti M, Cossarini F, Bigoloni A, Cinque P, Bossolasco S, Travi G, Fumagalli L, Lazzarin A, Castagna A. Ten-year survival among HIV-1 infected subjects with AIDS or non-AIDS-defining malignancies. Int J Cancer. 2012;130:2990–6.PubMedCrossRefGoogle Scholar
  25. Zoufaly A, Stellbrink H-J, van der Heiden M, Kollan C, Hoffmann C, van Lunzen J, Hamouda O, and the ClinSurv Study Group. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis. 2009;200:79–87.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of Epidemiology and Prevention, Institute of Human VirologyUniversity of Maryland School of MedicineBaltimoreUSA